A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma
In patients with metastatic EAC, single agent niraparib as second line therapy is not an effective option.
Authors
- Bryan P. Schneider (ORCID: https://orcid.org/0000-0003-1868-7739)
- Susan M. Perkins (ORCID: https://orcid.org/0000-0002-5842-4354)
- Heather Burney
- Hirva Mamdani (ORCID: https://orcid.org/0000-0003-3874-8703)
- Christos Fountzilas (ORCID: https://orcid.org/0000-0003-3837-5644)
- Shadia I. Jalal (ORCID: https://orcid.org/0000-0001-8938-7077)
- Ahmed Bilal Khalid
- Christopher A. Fausel (ORCID: https://orcid.org/0000-0002-4564-0197)
Institutions
- Indiana University Health (US)
- Roswell Park Comprehensive Cancer Center (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3389/fonc.2024.1435056
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.85